Grail survives adcomm vote as it awaits FDA decision for cancer blood test

Despite a major trial setback earlier this year and increasing questions over its efficacy, medtech Grail has beaten the odds and seen a positive recommendation for its multi-cancer blood test Galleri from FDA advisors.